|
시장보고서
상품코드
2078342
옥트레오타이드 시장 규모, 점유율 및 성장 분석 : 제형별, 적응증별, 유통경로별, 최종사용자별, 제품 유형별, 지역별 - 업계 예측(2026-2033년)Octreotide Market Size, Share, and Growth Analysis, By Formulation (Immediate Release Injectable, Long-Acting Release Depot), By Indication, By Distribution, By End-User, By Product Type, By Region - Industry Forecast 2026-2033 |
||||||
세계의 옥트레오타이드 시장 규모는 2024년에 18억 2,000만 달러로 평가되었고, 2025년 19억 1,000만 달러에서 2033년까지 28억 5,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 5.12%를 기록할 전망입니다.
세계 옥트레오타이드 시장은 신경내분비종양의 발생률 증가와 의사가 환자의 복약 순응도를 높이는 제제를 채택하는 경향이 강해지고 있는 것을 배경으로 크게 확대되고 있습니다. 당초에는 틈새 시장인 병원 및 약국으로 한정되었던 옥트레오타이드가 현재는 널리 유통되는 제품으로 발전했으며, 주요 지역에서 서방형 주사제가 규제 당국의 승인을 받은 것은 맞춤형 의료로의 전환을 반영하고 있습니다. 보험사가 주사용 바이오의약품에 대한 수용을 확대한 것도 수요를 뒷받침했으며, 옥트레오타이드는 내분비 요법 분야의 혁신을 상징하는 존재가 되었습니다. 또한, 외래에서 받는 수액 치료 서비스와 휴대용 자동 주사기의 등장으로 환자들은 집에서 간편하게 치료를 받을 수 있게 되었으며, 단시간 작용형 및 장시간 작용형 데포 제제의 개발이 모두 촉진되고 있습니다. 신흥 시장의 제조업체와 유통업체 간의 협력을 통해 접근성과 합리적인 가격이 더욱 향상되고 있습니다.
세계 옥트레오타이드 시장의 성장 요인
호르몬 분비성 신경내분비 종양의 유병률이 증가함에 따라 표적 치료제인 옥트레오타이드에 대한 수요가 크게 높아졌으며, 임상의들은 증상 완화 및 종양 진행 억제를 목적으로 다양한 치료 프로토콜에 이 약물을 도입하고 있습니다. 이러한 추세에 따라 환자 수가 증가하고 있으며, 의료 종사자들은 다양한 임상 현장에서 옥트레오타이드를 도입하고 있습니다. 그 결과, 처방 활동이 증가하고 있으며, 치료 용도의 확대와 전문의들 사이에서 인지도가 높아짐에 따라 시장 확대의 기회가 생겨나고 있습니다. 또한, 옥트레오타이드가 환자의 삶의 질(QOL)을 향상시키는 데 효과적임이 입증됨에 따라, 다직종 협력을 통한 치료 체계에 이를 더욱 적극적으로 도입하고 있습니다.
세계 옥트레오타이드 시장의 제약 요인
세계 옥트레오타이드 시장은 복잡한 제조 공정과 제한된 경쟁으로 인해 큰 과제에 직면해 있습니다. 그 결과, 가격이 급등하여 의료 예산과 환자 모두에게 부담이 되고 있습니다. 이 때문에 특히 가격에 민감한 시장에서는 의약품 채택 기준에 신중하게 포함시키거나 보험 급여 방침을 엄격히 적용하는 경향이 나타나고 있어, 본 제제의 보다 광범위한 보급을 저해하고 있습니다. 의료진은 더 저렴한 대체 약물을 선택하거나 치료 시작을 연기할 가능성이 있습니다. 또한, 경제적 고려로 인해 임상의가 옥트레오타이드 처방을 주저하게 되어, 결국 처방량 감소로 이어질 우려가 있습니다. 이러한 경제적 장벽은 예산 편성 결정에 영향을 미치며, 그 결과 비용 대비 효과가 더 높은 치료법이 우선시되고 있습니다.
세계 옥트레오타이드 시장 동향
세계 옥트레오타이드 시장에서는 치료 적응증의 확대라는 뚜렷한 추세가 나타나고 있습니다. 이러한 급증은 효과적인 증상 완화에 대한 임상의들의 신뢰가 높아지고 환자 수요가 증가함에 따라 촉진되고 있으며, 난치성 위장관 출혈이나 다양한 호르몬 장애 등의 질환에서 적응증 외 사용이 늘어나는 결과로 이어지고 있습니다. 그 결과, 각 제조업체는 특정 대상을 대상으로 한 임상 조사에 더 많은 자원을 투입하여 제품 파이프라인을 확대하는 한편, 전문의들과의 협력을 강화하고 있습니다. 이러한 전략적 접근 방식은 시장 침투율을 높일 뿐만 아니라, 다양한 치료 분야에 걸쳐 안정적인 수익 기반을 구축하는 것을 목표로 하고 있으며, 이를 통해 전 세계 이해관계자들과의 장기적인 관계를 공고히 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 옥트레오타이드 시장 규모 : 제제별
세계의 옥트레오타이드 시장 규모 : 적응증별
세계의 옥트레오타이드 시장 규모 : 유통별
세계의 옥트레오타이드 시장 규모 : 최종사용자별
세계의 옥트레오타이드 시장 규모 : 제품 유형별
세계의 옥트레오타이드 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Octreotide Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 1.91 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 5.12% during the forecast period (2026-2033).
The global octreotide market has expanded significantly, driven by the rising incidence of neuroendocrine tumors and the increasing physician adoption of formulations that improve patient compliance. Originally confined to niche hospital pharmacies, octreotide has evolved into a widely distributed product, with depot injections gaining regulatory approval across major regions, reflecting the shift toward personalized medicine. The growing acceptance of injectable biologics by payers has also bolstered demand, transforming octreotide into a symbol of innovation in endocrine therapy. Additionally, the advent of outpatient infusion services and portable autoinjectors has enabled patients to receive treatments conveniently at home, fostering the development of both short-acting and long-acting depot products. Collaborations between manufacturers and distributors in emerging markets further enhance accessibility and affordability.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Octreotide market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Octreotide Market Segments Analysis
Global octreotide market is segmented by formulation, indication, distribution, end-user, product type and region. Based on formulation, the market is segmented into Immediate Release (IR) Injectable, Long-Acting Release (LAR) Depot and Subcutaneous Implant. Based on indication, the market is segmented into Acromegaly, Carcinoid Tumors, Variceal Bleeding and Diarrhea (VIPoma). Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Hospitals and Endocrinology Clinics. Based on product type, the market is segmented into Branded (Sandostatin) and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Octreotide Market
The rising prevalence of hormone-secreting neuroendocrine tumors has significantly enhanced the demand for octreotide as a targeted treatment, prompting clinicians to incorporate this medication into various treatment protocols for alleviating symptoms and suppressing tumor progression. This trend has led to a growing patient population, encouraging healthcare professionals to employ octreotide across a range of clinical environments. Consequently, there is an increase in prescribing activities, presenting opportunities for market expansion through heightened therapeutic applications and greater awareness among specialists. Furthermore, the acknowledged effectiveness of octreotide in enhancing patients' quality of life is further driving its integration within multidisciplinary care frameworks.
Restraints in the Global Octreotide Market
The global octreotide market faces significant challenges due to its intricate manufacturing process and limited competition, leading to high pricing that creates pressure on both healthcare budgets and patients. As a result, there tends to be cautious formulary placements and restrictive reimbursement policies that hinder the drug's broader adoption, especially in markets sensitive to pricing. Health care providers may opt for more affordable alternatives or postpone initiating therapy, while economic considerations can deter clinicians from recommending octreotide, ultimately causing a decline in prescription volumes. This financial barrier influences budgeting decisions, resulting in a preference for more cost-effective treatments.
Market Trends of the Global Octreotide Market
The Global Octreotide market is experiencing a notable trend towards the expanding landscape of therapeutic indications. This surge is fueled by rising clinician confidence and patient demand for effective symptom relief, leading to increased off-label usage for conditions such as refractory gastrointestinal bleeding and various hormonal disorders. As a result, manufacturers are committing more resources to targeted clinical research, broadening their product pipelines, and fostering collaborations with specialty physicians. This strategic approach not only enhances market penetration but also aims to establish a stable revenue base across diverse therapeutic areas, thereby solidifying long-term stakeholder relationships across the globe.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Octreotide Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Immediate Release (IR) Injectable
- Long-Acting Release (LAR) Depot
- Subcutaneous Implant
Global Octreotide Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Acromegaly
- Carcinoid Tumors
- Variceal Bleeding
- Diarrhea (VIPoma)
Global Octreotide Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Octreotide Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Endocrinology Clinics
Global Octreotide Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Branded (Sandostatin)
- Biosimilars
Global Octreotide Market Size & CAGR (2026-2033)
- North America (Formulation, Indication, Distribution, End-User, Product Type)
- US
- Canada
- Europe (Formulation, Indication, Distribution, End-User, Product Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Formulation, Indication, Distribution, End-User, Product Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Formulation, Indication, Distribution, End-User, Product Type)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Formulation, Indication, Distribution, End-User, Product Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Novartis AG (Sandostatin)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bachem Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BCN Peptides
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PolyPeptide Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz (Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hospira (Pfizer)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
